A budget proposed by President Donald Trump would set NIH and biomedical research back 15 years, said former Vice President Joe Biden, addressing members of the American Association for Cancer Research on April 3.
It's fair to say that eight years ago, when the Obama administration infused the economy with $800 billion in stimulus funding, policymakers likely did not expect the health information technology industry to evolve into fiefdoms guarded by legions of lawyers and walls of proprietary code.
The White House budget blueprint to slash NIH funding by 18.3 percent in fiscal 2018 is just a proposal, NCI Acting Director Douglas Lowy said at the meeting of the Board of Scientific Advisors March 21.
FDA may have escaped the devastating cuts in President Trump's first budget proposal, while NIH ended up taking the brunt of its fury.
Ronald DePinho announced on March 8 that he will be stepping down as president of MD Anderson Cancer Center.DePinho's five-and-a-half years at the helm of the world's largest cancer center were marked by unprecedented turbulence, questions of conflicts of interest, and unhappiness on the part of the faculty.
Steve Hahn didn't apply for the job of Chief Operating Officer at MD Anderson Cancer Center. In fact, there was no COO job to apply to, and conversations that preceded the announcement of his new role took less than a week.
FDA's passive reliance on self-reporting by hospitals and device manufacturers allowed harm caused by power morcellators to go unnoticed for over two decades—likely contributing to injury and deaths of hundreds of women, according to the U.S. Government Accountability Office said.
Audit: Lynda Chin’s abandoned $62 million IBM Watson collaboration didn’t follow standard procedures
An audit of an abandoned mega-project run by IBM Watson and MD Anderson Cancer Center found that the Houston-based institution skirted the UT System's procurement regulations as it spent $62.1 million on an ill-fated artificial intelligence system.
It took the Multiple Myeloma Research Foundation nearly a decade and over $40 million to create what the foundation describes as the largest disease-specific cancer genome dataset in existence.
Overnight, cancer pharmaceuticals billionaire Patrick Soon-Shiong stopped using the trademark “MoonShot” to describe his health initiatives, opting instead to use the less grabby, but equally ambitious, name “cancer breakthroughs.”
